Lantheus begins trials of F-18 cardiac agent

Twitter icon
Facebook icon
LinkedIn icon
e-mail icon
Google icon

Lantheus Medical Imaging announced the initiation of a Phase 1 clinical study to assess the safety, dosimetry and tolerability of LMI1195, an F-18 small molecule tracer for PET imaging of cardiac neuronal function.

The Phase 1 open-label, non-randomized, single-dose study will be conducted in the United States. The study is designed to estimate the radiation dosimetry of LMI1195 in healthy subjects undergoing a PET scan and will evaluate the safety and tolerability of the tracer, gather pharmacokinetic and metabolic data, and assess PET imaging parameters and image quality, the company said.

According to Don Kiepert, Lantheus' president and CEO, LMI1195 is the firm's second product to enter clinical development that uses molecular imaging and PET technology for cardiovascular imaging.